Terms: = Prostate cancer AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Diagnosis
3 results:
1. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed HU; El-Shater Bosaily A; Brown LC; Gabe R; Kaplan R; Parmar MK; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham AP; Oldroyd R; Parker C; Emberton M;
Lancet; 2017 Feb; 389(10071):815-822. PubMed ID: 28110982
[TBL] [Abstract] [Full Text] [Related]
2. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.
Félix J; Andreozzi V; Soares M; Borrego P; Gervásio H; Moreira A; Costa L; Marcelo F; Peralta F; Furtado I; Pina F; Albuquerque C; Santos A; Passos-Coelho JL;
Value Health; 2011 Jun; 14(4):499-505. PubMed ID: 21669375
[TBL] [Abstract] [Full Text] [Related]
3. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.
Landmann C; Hunig R
Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):1073-6. PubMed ID: 2478510
[TBL] [Abstract] [Full Text] [Related]
